reviewed april 2026|next review october 2026|88 physicians psi has verified|11637 published studies
Cathelicidin Peptides
Cathelicidins are a family of naturally occurring (the body's own) antimicrobial peptides stored as inactive precursors in neutrophil granules and epithelial cells, with LL-37 as the only human member, and a well-established vitamin D regulatory connection that explains part of how vitamin D supports immune function.
Evidence landscape: 11637 published studies
Published studies span innate immunology, vitamin D biology, and antimicrobial peptide drug development. Extensive research across species.
- 6 Human
- 169 Animal
- 25 Reviews
- 11437 Other research
Not FDA-approved as a therapeutic. Cathelicidins are naturally occurring (the body's own) immune peptides. Therapeutic cathelicidin analogs are in animal development. No cathelicidin-based antibiotic has entered clinical trials.
Not available as a therapeutic product. The body produces cathelicidins naturally, and vitamin D supplementation can increase production. For the human-specific compound LL-37, see PSI's LL-37 page.
This is a family page covering cathelicidins across species. LL-37 is the only human cathelicidin. The vitamin D connection (CAMP gene promoter contains a vitamin D response element) is one of the best-characterized mechanisms explaining how vitamin D supports immune defense. Cathelicidin-derived peptides are being studied as templates for new antibiotics.
PSI Assessment
The human body produces its own antibiotics. Cathelicidins are antimicrobial peptides stored in immune cells and released when infection is detected. They kill bacteria by physically puncturing their membranes, a mechanism that bacteria struggle to develop resistance against. LL-37, the only human cathelicidin, is covered in detail on its own PSI page. This page covers the broader cathelicidin family and one of the most important connections in immune biology: vitamin D directly increases cathelicidin production through a well-characterized genetic mechanism. This is one of the clearest explanations for how vitamin D deficiency impairs immune function.
Built-in antibiotics. Vitamin D directly increases production through a well-characterized genetic mechanism. LL-37 is the human member. Cathelicidin-derived antibiotics are in animal development.
Cathelicidins are cationic antimicrobial peptides characterized by a conserved cathelin pro-domain. The active peptide is released by protease cleavage from the inactive precursor (hCAP-18 in humans). LL-37, the mature human cathelicidin, kills bacteria via membrane disruption, modulates immune responses by recruiting neutrophils and activating dendritic cells, stimulates angiogenesis (blood vessel formation), and enhances wound healing. Vitamin D induces cathelicidin expression via a vitamin D response element in the CAMP gene promoter, directly linking vitamin D status to antimicrobial peptide production.
What the evidence supports
Cathelicidins are essential components of innate immune defense with a well-characterized membrane-disrupting mechanism documented across species. LL-37 (the only human cathelicidin) has extensive research. Vitamin D directly induces cathelicidin/LL-37 expression through a vitamin D response element in the CAMP gene promoter. This is validated in human studies. The antimicrobial activity against gram-positive and gram-negative bacteria, enveloped viruses, and fungi is reproducible.
What is not yet established
Whether cathelicidin-based antibiotics can achieve clinical development with acceptable therapeutic windows between antimicrobial activity and host cell toxicity. Whether vitamin D supplementation to boost cathelicidin levels meaningfully reduces infection rates in clinical practice. Optimal formulation for cathelicidin-derived therapeutics given stability and delivery challenges.
Research Evidence
The findings below cover the antimicrobial mechanism, the vitamin D regulatory connection, and the therapeutic development potential.
Evidence by condition
Evidence dimensions across innate immunity, vitamin D connection, and antibiotic development. The vitamin D axis has the strongest human data. Therapeutic development is at the animal study stage.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Innate Immunity | ||||
| Antimicrobial Drug Development | ||||
| Vitamin D-Immune Axis | ||||
| Antibiotic Development Templates |
Cathelicidins kill gram-positive and gram-negative bacteria, enveloped viruses, and fungi through membrane disruption. The physical mechanism of action makes resistance development difficult, a significant advantage over conventional antibiotics.
The antimicrobial mechanism is well-characterized across the family. Multiple species produce cathelicidins with similar mechanisms but different sequences, reflecting evolutionary conservation of this immune defense strategy.
Vitamin D directly induces cathelicidin/LL-37 expression through a vitamin D response element in the CAMP gene promoter. Vitamin D supplementation increases LL-37 levels in human subjects. This mechanism explains part of the association between vitamin D deficiency and infection susceptibility.
The vitamin D-cathelicidin connection is one of the best-characterized mechanisms linking a nutrient to immune function. It has been validated in human supplementation studies.
Cathelicidin-derived antimicrobial peptides are in animal development as next-generation antibiotics. Structure-activity studies have identified key features for balancing antimicrobial potency with selectivity over host cells.
The therapeutic development faces manufacturing cost, stability, and delivery challenges. No cathelicidin-based antibiotic has entered clinical trials. The antimicrobial resistance crisis provides strong motivation for this research direction.
6 Human|169 Animal|25 Reviews
View all 11637 indexed studiesHow Cathelicidin Peptides Works
Cathelicidins are naturally occurring (the body's own) cationic antimicrobial peptides. They kill microbes through membrane disruption and modulate immune responses. Vitamin D regulates cathelicidin expression through a vitamin D response element in the CAMP gene promoter.
Cathelicidins are built-in antibiotics stored in immune cells and released when infection is detected. They kill bacteria by puncturing their membranes, a physical attack that bacteria struggle to develop resistance against. Vitamin D directly increases cathelicidin production, one of the clearest explanations for how vitamin D supports immune function.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Cathelicidins are cationic antimicrobial peptides characterized by a conserved cathelin pro-domain. The active peptide is released by protease cleavage. LL-37 (human) kills bacteria via membrane disruption, modulates immune responses, promotes wound healing, and has anti-biofilm activity. Vitamin D induces cathelicidin expression via the vitamin D response element in the CAMP gene promoter.
What is Cathelicidin Peptides being studied for?
Researchers are studying Cathelicidin Peptides across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Cathelicidin Peptides overall. This means a compound can have human studies for one condition but only animal data for another.
Innate Immunity
·Human TrialsCathelicidins are essential first-line immune defense molecules expressed in neutrophils, macrophages, and epithelial cells. LL-37 (the human member) kills bacteria and recruits immune cells.
Limitations: Understanding cathelicidin biology has not yet translated into clinical antimicrobial therapies. See the LL-37 page for detailed human-specific data.
Antimicrobial Drug Development
·Human TrialsCathelicidin-derived peptides are being developed as novel antibiotics. The membrane-disrupting mechanism makes resistance development difficult, a significant advantage over conventional antibiotics.
Limitations: Manufacturing cost, stability, and systemic delivery remain challenges. No cathelicidin-based antibiotic is FDA-approved or in clinical trials.
Vitamin D-Immune Axis
·Animal StudiesVitamin D directly induces cathelicidin/LL-37 expression. This is one of the best-characterized mechanisms explaining how vitamin D supports immune function. Human supplementation studies confirm the pathway.
Limitations: Whether vitamin D supplementation to increase cathelicidin levels reduces infection risk is supported by some but not all clinical trials. The relationship is real but complex and context-dependent.
Antibiotic Development Templates
·PreclinicalMultiple cathelicidin-derived antimicrobial peptides are in animal development. Structure-activity studies have identified key features for antimicrobial potency and selectivity.
Limitations: No cathelicidin-based antibiotic has entered clinical trials. The transition from animal-stage antimicrobial peptide to clinical antibiotic is a well-known development challenge.
Safety and Regulatory Status
FDA Status: Not FDA-approved as a therapeutic. Cathelicidins are naturally occurring (the body's own) immune peptides. Therapeutic analogs are in animal development.
Availability: Not available as a therapeutic product. Vitamin D supplementation can increase natural cathelicidin production within normal physiological ranges. See the LL-37 page for the human-specific compound.
Class context: Cathelicidins are naturally occurring (the body's own) immune peptides with no safety concerns from normal physiology. Dose-dependent cytotoxicity at high concentrations is the primary challenge for therapeutic development.
Cathelicidins are naturally occurring (the body's own) immune peptides. Vitamin D supplementation to support cathelicidin production is generally safe within recommended dosing ranges. Therapeutic cathelicidin-derived antibiotics face the standard antimicrobial peptide challenge of balancing efficacy with host cell toxicity.
Questions and Comparisons
Questions the evidence raises for a Cathelicidin Peptides discussion.
Comparison and Related Research
Cathelicidins are compared with LL-37 (the human member) and other antimicrobial peptide families.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Comprehensive review establishing cathelicidins as a major family of host defense peptides in mammalian innate immunity. The human cathelicidin LL-37, the sole member in humans, functions as both a direct antimicrobial agent and an immunomodulator that bridges innate and adaptive immune responses.Zanetti M., 2004 in J Leukoc Biol. View on PubMed
- 2.Clinical review of cathelicidin expression in human skin and its role in dermatological conditions. Reduced cathelicidin expression was linked to increased susceptibility to skin infections in atopic dermatitis, while overexpression in rosacea contributed to inflammatory pathology, demonstrating the importance of balanced cathelicidin levels.Schauber J et al., 2007 in J Allergy Clin Immunol. View on PubMed
- 3.Landmark study showing that toll-like receptor activation in human macrophages upregulates cathelicidin expression through the vitamin D pathway. This finding explained why vitamin D deficiency increases infection susceptibility and established cathelicidin as the key effector molecule linking vitamin D status to antimicrobial defense.Liu PT et al., 2006 in Science. View on PubMed
- 4.Extensive review of LL-37, the mature form of human cathelicidin, covering its antimicrobial spectrum, wound healing promotion, angiogenesis stimulation, and immunomodulatory functions. The review catalogued activity against Gram-positive and Gram-negative bacteria, fungi, viruses, and mycobacteria.Vandamme D et al., 2012 in Cell Immunol. View on PubMed
- 5.Clinical study in patients with atopic dermatitis comparing those who developed eczema herpeticum (disseminated herpes simplex infection) to those who did not. Reduced cathelicidin expression in skin biopsies was significantly associated with susceptibility to viral superinfection, establishing a direct clinical consequence of cathelicidin deficiency.Howell MD et al., 2006 in J Invest Dermatol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.